Clinical Trials Browser

BRCA1 Mutation

NCT03613532 2026-05-20

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Phase 1 Active not recruiting

102 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06191978 2026-05-15

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 1 Recruiting

40 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02998567 2026-05-12

HyPeR

Phase 1 Active not recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05396859 2026-04-27

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Phase 1 Active not recruiting

13 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03922555 2026-04-16

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Phase 1 Recruiting

18 enrolled

CNS

Central Nervous System Neoplasms

NCT06327685 2026-04-01

Avapritinib With Decitabine in Patients With SM-AHN

Phase 1 Recruiting

34 enrolled

MyeloidOther hematologic neoplasm

Systemic Mastocytosis With an Associated Hematologic Neoplasm

NCT04980404 2026-03-30

Inqovi Maintenance Therapy in Myeloid Neoplasms

Phase 1 Active not recruiting

22 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

NCT05010772 2026-01-14

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Phase 1 Recruiting

125 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05178693 2025-11-24

LANTana

Phase 1 Recruiting

27 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05037500 2025-11-12

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Phase 1 Terminated

8 enrolled

Genitourinary

Prostatic Neoplasms

NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Phase 1 Completed

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

HyPeR

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Avapritinib With Decitabine in Patients With SM-AHN

Inqovi Maintenance Therapy in Myeloid Neoplasms

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

LANTana

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer